A newly published study reveals a surprising connection between a specific molecule and the progression of skin cancer, particularly highlighting its role in enabling tumors to escape the immune system's defenses. This critical research was spearheaded by scientists at NYU Langone Health and its Perlmutter Cancer Center, demonstrating the significant influence of a transcription factor known as HOXD13 on melanoma tumor growth.
Transcription factors are proteins that play a vital role in regulating gene expression, essentially controlling how genetic information is translated into the proteins that form the building blocks of our bodies and facilitate communication within cells. The study, which appeared online in the journal Cancer Discovery on January 30, indicates that HOXD13 is pivotal for angiogenesis—the process through which new blood vessels develop to supply oxygen and nutrients to rapidly growing melanoma cells.
The findings show that HOXD13 activates several other signaling pathways that contribute to enhanced blood flow to tumors, which include key players like vascular endothelial growth factor (VEGF), semaphorin-3A (SEMA3A), and CD73. When the researchers inhibited HOXD13, they noted a significant reduction in tumor size, highlighting the molecule's crucial role in cancer proliferation.
In addition to its impact on tumor growth, the study uncovered that melanoma patients exhibiting high levels of HOXD13 had lower blood concentrations of cytotoxic T cells. These immune cells are essential for identifying and destroying abnormal cancer cells. Moreover, the ability of T cells to infiltrate tumors was diminished in patients with elevated HOXD13 activity, suggesting that this molecule not only fuels tumor growth but also hampers the immune system's capacity to combat cancer effectively.
Dr. Pietro Berico, a postdoctoral research fellow involved in the study, emphasized the importance of these findings: "Our research provides compelling evidence that the transcription factor HOXD13 significantly drives melanoma development while simultaneously suppressing T cell activity that is crucial for fighting the disease."
Furthermore, the investigation revealed that HOXD13 alters the tumor microenvironment, making it less conducive to immune activity. This is achieved by increasing levels of CD73, a protein that enhances adenosine production—a compound that acts to inhibit T cell function and restricts their access to the tumor. Upon disabling HOXD13, researchers observed an uptick in T cell infiltration within tumors.
Dr. Eva Hernando-Monge, the senior investigator of the study, stated, "These results support the idea that targeting both angiogenesis and adenosine receptor pathways could represent a promising new strategy for treating HOXD13-driven melanoma." She noted that clinical trials are currently underway to evaluate the safety, dosage tolerance, and effectiveness of medications that inhibit VEGF and adenosine receptors for melanoma and other cancers. Some of these trials even combine these inhibitors with immunotherapy drugs designed to enhance the immune system's ability to eliminate cancer cells.
Should these trials yield positive outcomes, Hernando-Monge's team intends to initiate further clinical investigations focused on using a combination of VEGF and adenosine receptor inhibitors specifically for treating melanoma cases with raised HOXD13 levels. Additionally, she plans to explore whether the VEGF and adenosine pathways could be viable targets for treating other types of cancers where HOXD13 is also elevated, such as certain glioblastomas, sarcomas, and osteosarcomas.
To conduct this comprehensive study, researchers examined tumors from over 200 melanoma patients across the United States, Brazil, and Mexico, aiming to identify which biological pathways were either heightened or diminished. Among these pathways, HOXD13 was notably prominent. Subsequent experiments utilizing mouse models and human melanoma cell lines confirmed that HOXD13 plays a critical role in activating the other pathways linked to angiogenesis and immune evasion. Further tests involving the inhibition of HOXD13, VEGF, and adenosine corroborated its significance in cancer growth and survival.
Funding for this pivotal research was provided through multiple National Institutes of Health grants, alongside contributions from various organizations dedicated to melanoma research. The collaborative effort included numerous researchers from NYU Langone and other institutions, working together to unravel the complexities of melanoma biology and potential treatment avenues.
